Hepatitis C virus gene sequencing as a tool for precise genotyping in the era of new direct antiviral agents
Francesca Ceccherini Silberstein, Velia Chiara Di Maio, Marianna Aragri, Marco Ciotti, Valeria Cento, Carlo Federico Perno – 14 May 2015
Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects
Grace Lai‐Hung Wong, Yee‐Kit Tse, Vincent Wai‐Sun Wong, Terry Cheuk‐Fung Yip, Kelvin Kam‐Fai Tsoi, Henry Lik‐Yuen Chan – 14 May 2015 – Widespread and long‐term use of oral nucleos(t)ide analogs (NAs) to treat chronic hepatitis B (CHB) brings about safety data in a real‐life setting. We aimed to determine the risks of renal and bone side effects in patients receiving or who have received NAs as CHB treatment. A territory‐wide cohort study using the database from Hospital Authority, the major provider of medical services in Hong Kong, was conducted.
Comment on “when to perform hepatic resection for intermediate‐stage hepatocellular carcinoma”
Lisa A. Spacek, Steven F. Solga – 14 May 2015
Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral load
Dong Hyun Sinn, Junggyu Lee, Juna Goo, Kyunga Kim, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik – 11 May 2015 – Controversy exists about whether antiviral therapy (AVT) should be recommended for compensated cirrhosis patients with chronic hepatitis B virus (HBV) infection and detectable, but low, serum HBV‐DNA levels.
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
Saleh A. Alqahtani, Nezam Afdhal, Stefan Zeuzem, Stuart C. Gordon, Alessandra Mangia, Paul Kwo, Michael Fried, Jenny C. Yang, Xiao Ding, Phillip S. Pang, John G. McHutchison, David Pound, K. Rajender Reddy, Patrick Marcellin, Kris V.
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials
Saleh A. Alqahtani, Nezam Afdhal, Stefan Zeuzem, Stuart C. Gordon, Alessandra Mangia, Paul Kwo, Michael Fried, Jenny C. Yang, Xiao Ding, Phillip S. Pang, John G. McHutchison, David Pound, K. Rajender Reddy, Patrick Marcellin, Kris V.
Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1
Sheng‐xian Yuan, Jie Wang, Fu Yang, Qi‐fei Tao, Jin Zhang, Li‐li Wang, Yuan Yang, Hui Liu, Zhen‐guang Wang, Qing‐guo Xu, Jia Fan, Lei Liu, Shu‐han Sun, Wei‐ping Zhou – 11 May 2015 – Tumor cells with stemness (stem‐cell) features contribute to initiation and progression of hepatocellular carcinoma (HCC), but involvement of long noncoding RNAs (lncRNAs) remains largely unclear. Genome‐wide analyses were applied to identify tumor‐associated lncRNA‐DANCR. DANCR expression level and prognostic values of DANCR were assayed in two HCC cohorts (China and Korea, n = 135 and 223).
Hepatocellular carcinoma risk in chronic hepatitis B virus–infected compensated cirrhosis patients with low viral load
Dong Hyun Sinn, Junggyu Lee, Juna Goo, Kyunga Kim, Geum‐Youn Gwak, Yong‐Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Byung Chul Yoo, Seung Woon Paik – 11 May 2015 – Controversy exists about whether antiviral therapy (AVT) should be recommended for compensated cirrhosis patients with chronic hepatitis B virus (HBV) infection and detectable, but low, serum HBV‐DNA levels.
Human keratin 8 variants promote mouse acetaminophen hepatotoxicity coupled with c‐jun amino‐terminal kinase activation and protein adduct formation
Nurdan Guldiken, Qin Zhou, Ozlem Kucukoglu, Melanie Rehm, Kateryna Levada, Annika Gross, Raymond Kwan, Laura P. James, Christian Trautwein, M. Bishr Omary, Pavel Strnad – 11 May 2015 – Keratins 8 and 18 (K8/K18) are the intermediate filaments proteins of simple‐type digestive epithelia and provide important cytoprotective function. K8/K18 variants predispose humans to chronic liver disease progression and poor outcomes in acute acetaminophen (APAP)‐related liver failure.